在COVID-19期间重症患者的MDR细菌病:MARTINI研究
Karolina Akinosoglou1,2,3, Christina Petropoulou1,2, Vasiliki Karioti4
1Department of Medicine, University of Patras, 26504 Patras, Greece.
Pathogens (Basel, Switzerland)
|November 27, 2025
概括
在重症监护室 (ICU) 的多药耐药性感染在COVID-19和非COVID-19患者之间进行了比较. 尽管COVID-19患者具有类似的病原体耐药性,但死亡率更高,这凸显了加强感染控制的必要性.
科学领域:
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
- 流行病学 流行病学
背景情况:
- 多抗药性 (MDR) 血流感染 (BSI) 是重症监护室 (ICU) 的重大威胁.
- 由于感染控制措施受到损害,COVID-19大流行可能加剧了MDR感染的发生率.
- 对于COVID-19和非COVID-19的ICU人群之间的MDRBSI存在有限的比较数据.
研究的目的:
- 为了比较COVID-19ICU和非COVID-19ICU的成人患者中MDRBSI的特征,耐药性模式和结果.
- 在COVID-19大流行期间,确定MDRBSI患者在ICU死亡率的独立预测因素.
主要方法:
- 从2020年到2022年在第三级医院进行的回顾性观察性研究 (MARTINI).
- 包括接受COVID-19和非COVID-19重症监护室的MDRBSI成年患者.
- 对人口统计,并发病,严重性得分,微生物学,耐药性模式和结果的分析,用于死亡率预测因素的多变量回归.
主要成果:
- 与非COVID-19 ICU患者相比,COVID-19 ICU患者年龄较大,并发病率和严重程度得分较高.
- 格拉姆阴性病原体,主要是*Acinetobacter baumannii*和*Klebsiella pneumoniae*,在两组中都占主导地位,耐药性相似.
- 在COVID-19 ICU患者 (74.5%) 和非COVID-19 ICU患者 (38%) 之间,ICU死亡率显著更高.
- 年龄,SOFA分数,SIRS和COVID-19感染是死亡率的独立预测因素.
结论:
- 尽管有类似的病原体概况和耐药性,但COVID-19 ICU 患者的MDR BSI死亡率明显更高.
- COVID-19感染是患有MDR BSI的重症患者死亡率的独立预测因素.
- 加强感染控制方案和及时,有针对性的抗微生物治疗对于减轻重症患者中MDR细菌病风险至关重要.
更多相关视频
09:17Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
Published on: May 2, 2017
9.3K
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
3.1K
相关概念视频
01:30Pneumonia III: Complications and Assessment
765
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
765
01:28Pneumonia IV: Management
735
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
735
01:29Pneumonia II: Pathophysiology
2.5K
The pathophysiology of pneumonia involves the following steps:
2.5K